This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Luft, F. C. Search for Related Content PubMed PubMed Citation Articles by Luft, F. C. Related Collections ACE/Angiotension receptors Pathophysiology Gene expression Gene regulation Smooth muscle proliferation and differentiation Oxidant stress

(Hypertension. 2001;37:594.)
© 2001 American Heart Association, Inc.

Scientific Contributions

Workshop: Mechanisms and Cardiovascular Damage in Hypertension

Friedrich C. Luft

From Franz Volhard Clinic and Max Delbrück Center for Molecular Medicine, Medical Faculty of the Charité, Humboldt University of Berlin, Germany.

Correspondence to Friedrich C. Luft, MD, Wiltberg Strasse 50, 13125 Berlin, Germany. E-mail luft{at}fvk-berlin.de

Angiotensin (Ang) II is considered a regulatory hormone stimulating vascular smooth muscle cell constriction, aldosterone release from the adrenal gland, and sodium reabsorption in the renal tubule. Furthermore, Ang II may be formed and act locally as a chemokine, inducing tyrosine phosphorylation, cell growth, hypertrophy, and differentiation. In addition, evidence has recently accrued showing that Ang II is important in stimulating the production of reactive oxygen species and the activation of ancient inflammatory mechanisms. The transcription factor nuclear factor -B is pivotal to these processes. Nuclear factor -B activation stimulates the expression of a gene menagerie important to chemoattraction, surface adhesion molecule expression, coagulation, and inflammation. Anti-inflammatory interventions may have therapeutic utility.

Key Words: angiotensin • hypertension, experimental • animals, transgenic • aldosterone

This article has been cited by other articles:

				A. Vaajanen, H. Vapaatalo, H. Kautiainen, and O. Oksala Angiotensin (1-7) Reduces Intraocular Pressure in the Normotensive Rabbit Eye Invest. Ophthalmol. Vis. Sci., June 1, 2008; 49(6): 2557 - 2562. [Abstract] [Full Text] [PDF]

				Y. Yu, Y.-M. Kang, Z.-H. Zhang, S.-G. Wei, Y. Chu, R. M. Weiss, and R. B. Felder Increased Cyclooxygenase-2 Expression in Hypothalamic Paraventricular Nucleus in Rats With Heart Failure: Role of Nuclear Factor {kappa}B Hypertension, March 1, 2007; 49(3): 511 - 518. [Abstract] [Full Text] [PDF]

				S. D. Crowley, S. B. Gurley, M. J. Herrera, P. Ruiz, R. Griffiths, A. P. Kumar, H.-S. Kim, O. Smithies, T. H. Le, and T. M. Coffman Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney PNAS, November 21, 2006; 103(47): 17985 - 17990. [Abstract] [Full Text] [PDF]

				A. Harte, P. McTernan, R. Chetty, S. Coppack, J. Katz, S. Smith, and S. Kumar Insulin-Mediated Upregulation of the Renin Angiotensin System in Human Subcutaneous Adipocytes Is Reduced by Rosiglitazone Circulation, April 19, 2005; 111(15): 1954 - 1961. [Abstract] [Full Text] [PDF]

				B. Pitt A New HOPE for Aldosterone Blockade? Circulation, September 28, 2004; 110(13): 1714 - 1716. [Full Text] [PDF]

				K. Sekiguchi, X. Li, M. Coker, M. Flesch, P. M Barger, N. Sivasubramanian, and D. L Mann Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure Cardiovasc Res, August 15, 2004; 63(3): 433 - 442. [Abstract] [Full Text] [PDF]

				G. G. Neri Serneri, M. Boddi, P. A. Modesti, M. Coppo, I. Cecioni, T. Toscano, M. L. Papa, M. Bandinelli, G. F. Lisi, and M. Chiavarelli Cardiac Angiotensin II Participates in Coronary Microvessel Inflammation of Unstable Angina and Strengthens the Immunomediated Component Circ. Res., June 25, 2004; 94(12): 1630 - 1637. [Abstract] [Full Text] [PDF]

				T. Mori and A. W. Cowley Jr. Role of Pressure in Angiotensin II-Induced Renal Injury: Chronic Servo-Control of Renal Perfusion Pressure in Rats Hypertension, April 1, 2004; 43(4): 752 - 759. [Abstract] [Full Text] [PDF]

				T. Mori and A. W. Cowley Jr. Renal Oxidative Stress in Medullary Thick Ascending Limbs Produced by Elevated NaCl and Glucose Hypertension, February 1, 2004; 43(2): 341 - 346. [Abstract] [Full Text] [PDF]

				G. de Simone Left Ventricular Geometry and Hypotension in End-Stage Renal Disease: A Mechanical Perspective J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2421 - 2427. [Abstract] [Full Text] [PDF]

				G. E. Callera, R. M. Touyz, S. A. Teixeira, M. N. Muscara, M. H. C. Carvalho, Z. B. Fortes, D. Nigro, E. L. Schiffrin, and R. C. Tostes ETA Receptor Blockade Decreases Vascular Superoxide Generation in DOCA-Salt Hypertension Hypertension, October 1, 2003; 42(4): 811 - 817. [Abstract] [Full Text] [PDF]

				B. Pitt, C. T Stier Jr, and S. Rajagopalan Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 164 - 168. [Abstract] [PDF]

				M. T. Schram, N. Chaturvedi, C. Schalkwijk, F. Giorgino, P. Ebeling, J. H. Fuller, and C. D. Stehouwer Vascular Risk Factors and Markers of Endothelial Function as Determinants of Inflammatory Markers in Type 1 Diabetes: The EURODIAB Prospective Complications Study Diabetes Care, July 1, 2003; 26(7): 2165 - 2173. [Abstract] [Full Text] [PDF]

				J. Liu, F. Yang, X.-P. Yang, M. Jankowski, and P. J. Pagano NAD(P)H Oxidase Mediates Angiotensin II-Induced Vascular Macrophage Infiltration and Medial Hypertrophy Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 776 - 782. [Abstract] [Full Text] [PDF]

				G. Zalba, G. S. Jose, M. U. Moreno, M. A. Fortuno, A. Fortuno, F. J. Beaumont, and J. Diez Oxidative Stress in Arterial Hypertension: Role of NAD(P)H Oxidase Hypertension, December 1, 2001; 38(6): 1395 - 1399. [Abstract] [Full Text] [PDF]